<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652899</url>
  </required_header>
  <id_info>
    <org_study_id>2007LS138</org_study_id>
    <secondary_id>UMN-MT2007-19R</secondary_id>
    <secondary_id>UMN-WCC-53</secondary_id>
    <secondary_id>UMN-0712M23462</secondary_id>
    <nct_id>NCT00652899</nct_id>
  </id_info>
  <brief_title>Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer</brief_title>
  <official_title>MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, and total-body
      irradiation before a donor natural killer cell infusion helps stop the growth of tumor cells.
      It also helps stop the patient's immune system from rejecting the donor's natural killer
      cells. Aldesleukin may stimulate the natural killer cells to kill ovarian, fallopian tube, or
      primary peritoneal cancer cells. Treating the donor natural killer cells with aldesleukin may
      help the natural killer cells kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving laboratory-treated donor natural
      killer cells together with aldesleukin works when given after cyclophosphamide, fludarabine,
      and total-body irradiation in treating patients with recurrent and/or metastatic ovarian,
      fallopian tube, or primary peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the in vivo expansion of an infused allogeneic natural killer (NK) cell
           product following a preparative regimen comprising cyclophosphamide, fludarabine
           phosphate, and total-body irradiation in treating patients with recurrent and/or
           metastatic ovarian, fallopian tube, or primary peritoneal cancer.

      Secondary

        -  To characterize the quantitative and qualitative toxicities of this treatment regimen.

        -  To estimate disease response (complete or partial response) or clinical benefit (stable
           disease for &gt; 6 months) as measured by Response Evaluation Criteria in Solid Tumours
           (RECIST) criteria.

        -  To estimate time to progression and overall survival.

        -  To estimate the association between clinical response and donor/recipient KIR ligand
           matching status.

      Tertiary

        -  To evaluate immune activation of the in vivo expanded haploidentical allogeneic NK cells
           and its effect on the immune system.

      OUTLINE:

        -  Preparative regimen: Patients receive fludarabine phosphate IV on days 6 to 2 preceding
           natural killer (NK) cell infusion and cyclophosphamide IV on days 5 and 4 preceding NK
           cell infusion. Patients also undergo total-body irradiation on day 1 preceding NK cell
           infusion.

        -  Allogeneic natural killer (NK) cell administration and aldesleukin: Patients receive
           aldesleukin-activated haploidentical allogeneic NK cells intravenously (IV) on day 0.
           Beginning 4-6 hours after allogeneic NK cell infusion, patients receive aldesleukin
           subcutaneously (SC) 3 times a week for 6 doses.

      Patients achieving any initial response (complete or partial response) or a clinical benefit
      (stable disease for &gt; 6 months) who progress after 6 months may receive 1 re-treatment course
      as above.

      Blood samples are collected at baseline, on days 0, 7, 14, and 28, and then at 2 and 3 months
      post NK cell infusion for cytokine measurements, immunophenotyping, functional analyses, and
      testing for persistence of donor cells.

      After completion of study treatment, patients are followed periodically for at least 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to toxicity
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product</measure>
    <time_frame>Day 12-14</time_frame>
    <description>Detection of an absolute donor derived cell count of &gt; or = 100 cells/mL after NK cell infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Per Disease Response</measure>
    <time_frame>1 Month After Natural Killer Cell Infusion (Day 30)</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Complete Response (CR)-Disappearance of all target lesions (TL); Partial Response (PR)-&lt; or = 30% decrease in the sum of the longest diameter (LD) of TL, reference baseline sum LD; Stable Disease (SD)-Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference the smallest sum LD since the treatment started; Progressive Disease (PD)- &lt; or = 20% increase in the sum of the LD of TL, reference the smallest sum LD recorded since treatment started or appearance of &lt; or = 1 new lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days to Progression</measure>
    <time_frame>From date of first treatment to disease progression</time_frame>
    <description>Median number of days from first date of treatment to date of disease progression (appearance of new metastatic lesions or objective tumor progression). Defined by computated tomography (CT) imaging based on Response Evaluation Criteria In Solid Tumors (RECIST): Progressive Disease (PD) &gt; or = 20% increase in sum of all target or any new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Number of Days Patients Alive After Treatment</measure>
    <time_frame>From first date on-study (treatment) to date of death</time_frame>
    <description>Median number of days patients alive from date of treatment to date of death or date of last follow-up if censored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.
1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.
1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <other_name>Zyloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine phosphate</intervention_name>
    <description>25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <other_name>Fludarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>200 cGy Day 1 preceding natural killer cell infusion.</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic natural killer cells</intervention_name>
    <description>Given day 0 - dose of 1.5-8.0 * 10^7/kg</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <other_name>related donor haploidentical allogenic cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>10 MU 3 times/week for a total of 6 doses beginning Day 0</description>
    <arm_group_label>Total Body Irradiation</arm_group_label>
    <arm_group_label>No Total Body Irradiation</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of recurrent ovarian cancer, fallopian tube, or primary peritoneal cancer
             who meets the following criteria:

          -  Measurable disease (≥ 1 cm) per Response Evaluation Criteria for Solid Tumors (RECIST)
             - patients with bone as their only site of metastatic disease will not be eligible

          -  Progression on or failure to respond to at least 2 salvage chemotherapy regimens (2
             regimens given for disease recurrence) for recurrent/metastatic ovarian, fallopian
             tube, or primary peritoneal cancer

          -  If history of brain metastases, stable for at least 3 months after treatment - A brain
             computed tomography (CT) scan will only be required in subjects with known brain
             metastases at the time of enrollment or in subjects with new clinical signs or
             symptoms suggestive of brain metastases.

          -  Available related HLA-haploidentical natural killer (NK) cell donor (by at least class
             I serologic typing). If biologic parents or siblings are available, can proceed with
             work-up of subject prior to return of human leukocyte antigen (HLA) typing results.

          -  Age 18 years or older

          -  Gynecology Oncology Group (GOG) performance status 0 or 1

          -  Adequate organ function as determined by the following criteria within 14 days of
             study enrollment:

               -  Bone marrow: platelets ≥ 80,000 x 10^9/L and hemoglobin ≥ 9g/dL, unsupported by
                  transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10^9/L, unsupported by
                  granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony
                  stimulating factor (GM-CSF)

               -  Renal function: creatinine (Cr) ≤ 2.0 mg/dL

               -  Liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
                  total bilirubin, alkaline phosphatase &lt; 5 times upper limit of institutional
                  normal

               -  Cardiac: Left ventricular ejection fraction &gt;40%

               -  Pulmonary function: &gt; 50% corrected Carbon Monoxide Diffusing Capacity (DLCO) and
                  Forced expiratory volume in one second (FEV1), if presence of pleural effusion
                  due to metastatic disease &gt;40% corrected DLCO and FEV1 acceptable.

          -  Able to be off prednisone or other immunosuppressive medications for at least 3 days
             prior to Day 0

          -  Voluntary written informed consent signed before performance of any study related
             procedure not part of normal medical care.

        Exclusion Criteria:

          -  Pregnant or lactating - The agents used in this study may be teratogenic to a fetus
             and there is no information on the excretion of agents into breast milk. All females
             of childbearing potential must have a blood test or urine study within 14 days prior
             to registration to rule out pregnancy.

          -  Active infection - subjects must be afebrile, off antibiotics, and with no
             uninvestigated radiologic lesions (infiltrates or lesions with negative cultures or
             biopsies are allowed).

        Human anti-mouse antibody (HAMA) monitoring: All subjects will be questioned about prior
        exposure to antibody therapy (including OKT3, Rituximab, Trastuzumab, etc). Responses will
        be recorded and reported to the FDA as part of the annual report. For subjects with no
        prior antibody therapy exposure, no further action will be taken. For subjects who have
        received previous antibody therapies 10 ml of serum (red top tube) will be drawn before
        starting therapy and banked per section 8.1. The presence of HAMA will not exclude a
        patient from the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa A. Geller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <results_first_submitted>August 20, 2010</results_first_submitted>
  <results_first_submitted_qc>August 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2010</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two patients did not receive all of study treatment per protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients Enrolled</title>
          <description>This group includes all patients consented to participate in this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treating physician decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients Enrolled</title>
          <description>This group includes all patients consented to participate in this study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product</title>
        <description>Detection of an absolute donor derived cell count of &gt; or = 100 cells/mL after NK cell infusion.</description>
        <time_frame>Day 12-14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ovarian/Fallopian Tube/Peritoneal Cancer Patients</title>
            <description>This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m^2 and fludarabine 25 mg/m^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 * 10^7 kg) and/or total body irradiation per protocol (200 Gy on Day 1 preceding natural killer cell infusion).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product</title>
          <description>Detection of an absolute donor derived cell count of &gt; or = 100 cells/mL after NK cell infusion.</description>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Per Disease Response</title>
        <description>Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Complete Response (CR)-Disappearance of all target lesions (TL); Partial Response (PR)-&lt; or = 30% decrease in the sum of the longest diameter (LD) of TL, reference baseline sum LD; Stable Disease (SD)-Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference the smallest sum LD since the treatment started; Progressive Disease (PD)- &lt; or = 20% increase in the sum of the LD of TL, reference the smallest sum LD recorded since treatment started or appearance of &lt; or = 1 new lesion.</description>
        <time_frame>1 Month After Natural Killer Cell Infusion (Day 30)</time_frame>
        <population>Includes 12 patients that completed treatment per protocol criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>No Total Body Irradiation</title>
            <description>This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m^2 and fludarabine 25 mg/m^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 * 10^7 kg) and no total body irradiation.</description>
          </group>
          <group group_id="O2">
            <title>Total Body Irradiation</title>
            <description>This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m^2 and fludarabine 25 mg/m^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 * 10^7 kg) and total body irradiation (200 Gy on Day 1 preceding natural killer cell infusion).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Per Disease Response</title>
          <description>Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Complete Response (CR)-Disappearance of all target lesions (TL); Partial Response (PR)-&lt; or = 30% decrease in the sum of the longest diameter (LD) of TL, reference baseline sum LD; Stable Disease (SD)-Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference the smallest sum LD since the treatment started; Progressive Disease (PD)- &lt; or = 20% increase in the sum of the LD of TL, reference the smallest sum LD recorded since treatment started or appearance of &lt; or = 1 new lesion.</description>
          <population>Includes 12 patients that completed treatment per protocol criteria.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days to Progression</title>
        <description>Median number of days from first date of treatment to date of disease progression (appearance of new metastatic lesions or objective tumor progression). Defined by computated tomography (CT) imaging based on Response Evaluation Criteria In Solid Tumors (RECIST): Progressive Disease (PD) &gt; or = 20% increase in sum of all target or any new lesions.</description>
        <time_frame>From date of first treatment to disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Total Body Irradiation</title>
            <description>This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m^2 and fludarabine 25 mg/m^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 * 10^7 kg) and no total body irradiation.</description>
          </group>
          <group group_id="O2">
            <title>Total Body Irradiation</title>
            <description>This group includes patients with recurrent ovarian, fallopian tube or primary peritoneal cancer who received at least one dose of chemotherapy (cyclophosphamide 60 mg/m^2 and fludarabine 25 mg/m^2 for 2 doses, and aldesleukin 10 million units for 6 doses), infusion of natural killer cells (1.5-8.0 * 10^7 kg) and total body irradiation (200 Gy on Day 1 preceding natural killer cell infusion).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days to Progression</title>
          <description>Median number of days from first date of treatment to date of disease progression (appearance of new metastatic lesions or objective tumor progression). Defined by computated tomography (CT) imaging based on Response Evaluation Criteria In Solid Tumors (RECIST): Progressive Disease (PD) &gt; or = 20% increase in sum of all target or any new lesions.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="8" upper_limit="200"/>
                    <measurement group_id="O2" value="90" lower_limit="69" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival Number of Days Patients Alive After Treatment</title>
        <description>Median number of days patients alive from date of treatment to date of death or date of last follow-up if censored.</description>
        <time_frame>From first date on-study (treatment) to date of death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Body Irradiation</title>
            <description>This group includes patients that received chemotherapy, infusion of natural killer cells and total body irradiation per protocol.</description>
          </group>
          <group group_id="O2">
            <title>No Total Body Irradiation</title>
            <description>This group includes patients that received chemotherapy, infusion of natural killer cells and no total body irradiation per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Number of Days Patients Alive After Treatment</title>
          <description>Median number of days patients alive from date of treatment to date of death or date of last follow-up if censored.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.5" lower_limit="144" upper_limit="199"/>
                    <measurement group_id="O2" value="291" lower_limit="8" upper_limit="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were monitored through the follow-up period; death was followed for up to 2 years after Day 1 treatment.</time_frame>
      <desc>Adverse event collection for the purposes of this study focused on targeted adverse events and unexpected adverse events at specific time points in relation to the NK cell infusion and post infusion IL-2 injections.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients Enrolled</title>
          <description>This group includes all patients consented to participate in this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>immune hemolytic anemia, drug-related hemolysis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Death - disease progression NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection - febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="29" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Positive blood culture with fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="80" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="42" subjects_affected="12" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="44" subjects_affected="12" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="115" subjects_affected="13" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="58" subjects_affected="11" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="45" subjects_affected="11" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Endpoint for association of clinical benefit response with donor/recipient KIR ligand matching status is not evaluable due to 0 complete responders.
Correlative laboratory objectives are irrelevant due to ineffectiveness of study regimen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa Geller, M.D.</name_or_title>
      <organization>University of Minnesota, Dept. Ob/Gyn</organization>
      <phone>612-626-3111</phone>
      <email>gelle005@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

